Skip to main content

Table 6 The incidence of respiratory symptoms as reported by symptom diary during 7 days following challenge for the safety population

From: The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline

Symptom / beta2agonist use

Mannitol

Hypertonic Saline

n

627 (%)

636 (%)

Daytime cough

352 (56.9)

365 (58.4)

Wheeze

270 (43.6)

280 (44.8)

Trouble breathing

270 (43.6)

262 (41.9)

Symptoms interfering with activities

172 (27.8)

178 (27.4)

Night time cough

212 (34.2)

236 (37.8)

Beta2 agonist use

319 (51.5)

333 (53.3)

Nebulised beta2 agonist

16 (2.6)

19 (3.0)